…are horrible fossil fueled vehicles, you might just be a Warmist
The blog of the day is The First Street Journal, with a post on due process of law gone missing.
It’s country women week!
THE AUTHOR
PAGES
Recent Comments
- Jl on If All You See…: “Which isn’t what you said earlier, sorry. When you’re talking about more voting for on person or the other, the…” Nov 24, 15:19
- david7134 on If All You See…: “LG, Jeff gets his kicks by getting you to respond to him. He is very sick. I desire to hear…” Nov 24, 15:14
- L.G.Brandon!, L.G.Brandon! on If All You See…: “The problem here is I have no clue how to stop the filthy insults. Your problem is you’ve already used…” Nov 24, 14:12
- JimS on If All You See…: “If Trump can’t eliminate the Department of Education, he should restructure it to stomp on local boards that go woke…” Nov 24, 14:00
- Elwood P Dowd on If All You See…: “Abortionist, You know how to stop the personal observations, even though they are true. You must be bright enough to…” Nov 24, 13:53
3 down. 59 to go.
Thank you President Trump.
https://ktla.com/news/nationworld/u-s-puts-iowa-meth-kingpin-to-death-in-3rd-federal-execution-this-week/
Lolgf
Each of those executions is 100,000 votes.
She looks friendly… in a country way!
Potentially good news on the vaccine front.
https://marlin-prod.literatumonline.com/pb-assets/Lancet/pdfs/S0140673620316044.pdf
Oxford/AstraZeneca announced Phase I/II results showing their adenovirus-based SARS-CoV-2 spike protein vaccine stimulated both an antibody (humoral) response and a T-lymphocyte-mediated (cellular) response to the spike protein. They have a large Phase III trial ongoing. It’s possible to have a vaccine early in 2021!
In conclusion, ChAdOx1 nCoV-19 was safe, tolerated, and immunogenic, while reactogenicity was reduced with paracetamol (Tylenol). A single dose elicited both humoral
and cellular responses against SARS-CoV-2, with a booster immunisation augmenting neutralising antibody titres. The preliminary results of this first-in-human
clinical trial supported clinical development progression into ongoing phase 2 and 3 trials. Older age groups with comorbidities, health-care workers, and those with
higher risk for SARS-CoV-2 exposure are being recruited and assessed for efficacy, safety, and immunogenicity of ChAdOx1 nCoV-19 given as a single-dose or two-dose
administration regimen in further trials conducted in the UK and overseas. We will also evaluate the vaccine in children, once sufficient safety data have been accumulated in adult studies. Phase 3 trials are now underway in Brazil, South Africa, and the UK and will evaluate vaccine efficacy in diverse populations.